Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

02-132026

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...
02-032026

Bio-Thera and Avalon Pharma Execute Exclusive Commercialization Agreement for BAT3306, a Proposed Keytruda® Biosimilar for Saudi Arabia and MENA

Guangzhou, China/Riyadh, Saudi Arabia – February 3, 2026 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-st...
12-122025

Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion

•Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia®developed by Bio-Th...

上一页 1 2 3 4 5 ··· 下一页